**MINUTES**

**CPIC CONFERENCE CALL**

DATE: February 7, 2013

PRESENT: Andrea Gaedigk, Cyrine Haidar, David Kisor, Deana Kroetz, Ellie McDonagh, Howard McLeod, James Hoffman, Julie Johnson, Tom Callaghan, Kelly Caudle, Kevin Hicks, Kelly Filipski, Li Gong, Mary Relling, Mia Wadelius, Michelle Carrillo, Rachel Tyndale, Robert Freimuth, Samuel Johnson, Stuart Scott, Tammie Chang, Teri Klein, Todd Skaar.

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Update of authorship guideline | The CPIC Steering Committee approved changing the corresponding author email address to “cpic@PharmGKB.org” email address. The guidelines will still have the individual’s (senior author’s) name listed as corresponding author but the corresponding email address will be cpic@pharmgkb.org. This will help PharmGKB/CPIC better track manuscript submissions, copyright forms being signed, need for corrections, etc. Any email sent to this address would be forwarded by PharmGKB to the corresponding author to allow for their input; this would provide a mechanism for CPIC to track and be responsible for administration of CPIC guidelines. | Revised Authorship Guideline posted on the CPIC working group website. SOP updated to reflect this change. |
| Guidelines.gov deposits | We have submitted four of our guidelines (Codeine, Abacavir, Simvastatin, and Allopurinol) to guidelines.gov for consideration for inclusion. We chose to start with these guidelines as they will not be updated within the next 6 months (each update requires a new submission and the process from submission to post on guidelines.gov is approximately 20 weeks). | Kelly will follow-up on progress. |
| Pediatrics sections | New CPIC guidelines and updates of existing guidelines should include a section on pediatric recommendations (see minutes from December conference call). In cases of insufficient data, discussed using language that would not prohibit reimbursement or restrict access of the genetic test in this population (e.g. …, at the time of this writing there are no/sparse data available on this gene’s effects on this drug’s response in pediatric patient populations, although there is no reason to suspect that gene’s polymorphisms will affect this drug’s metabolism differently in children compared to adults.) | Kelly to incorporate into guideline template and remind authors of updates. |
| Updates on guidelines in progress | - CPIC G6PD-rasburicase guideline: Comments from authors/experts in field being addressed. Howard to be added as an author.  - TCA guideline: In press  - IL28B CPIC guideline: Discussed Table 2 (dosing recommendation) of the IL28B guideline draft and how to better incorporate an “actionable” recommendation.  - DPYD/5FU : Final draft circulated to all authors. Plan to circulate to CPIC members in next few weeks.  - allopurinol HLA: Published (http://www.pharmgkb.org/drug/PA448320)  - phenytoin CYP2C9/ HLA: Draft recommendation table 2 complete and being reviewed by writing team. Drafting Authorship Plan to be submitted to Steering Committee next week.  - HLA-CBZ: Circulated to CPIC members; Submitting to CPT early next week (2/11/2013)  -Ivacaftor/CFTR: Authorship plan approved by the CPIC Steering Committee; Writing underway.  Updates:  -Clopidogrel update: Final draft circulated to authors and will be circulated to CPIC group next week. (Submission deadline: end of February)  -Warfarin: PharmGKB has started to update the literature review/supplement. Coordination of the update is underway and additional authors are being invited to participate in the update. | IL28B guideline draft sent to Julie, Howard, Mia, and Tom for additional input from hepatologists at their institutions.  Kelly will submit authorship plan to Steering Committee  Julie will coordinate and follow-up on progress. |